Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
apoA-IV Double Nickase Plasmid (h): sc-402217-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- apoA-IV Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- apoA-IV Double Nickase Plasmid (h) and apoA-IV Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting APOA4. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: apoA-IV Antibody (G-8): sc-374543
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
apoA-IV Double Nickase Plasmid (h) | sc-402217-NIC | 20 µg | $410.00 | |||
apoA-IV Double Nickase Plasmid (h2) | sc-402217-NIC-2 | 20 µg | $410.00 |
APOA4 encodes apolipoprotein A-IV (apoA-IV), an intestine-derived, lipid-associated apolipoprotein that is secreted with chylomicrons and HDL-like particles during dietary fat absorption. apoA-IV contributes to lipoprotein remodeling and reverse cholesterol transport and influences triglyceride-rich lipoprotein metabolism through interactions with enzymes and transfer proteins that regulate lipid flux in plasma. Through these activities it links intestinal lipid handling to systemic lipid homeostasis and inflammatory signaling associated with atherosclerotic processes. Variation in APOA4 expression or function has been investigated in the context of dyslipidemia, cardiometabolic traits, and lipid-driven inflammatory states relevant to vascular and metabolic disease mechanisms.
apoA-IV Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the APOA4 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within APOA4. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt APOA4 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of APOA4-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.